Get the Stockscreener App
18.77
1.37%
-0.26
After Hours:
18.70
-0.07
-0.37%
Zai Lab Limited Adr stock is traded at $18.77, with a volume of 660.93K.
It is down -1.37% in the last 24 hours and up +2.07% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
See More
Previous Close:
$19.03
Open:
$18.69
24h Volume:
660.93K
Relative Volume:
0.80
Market Cap:
$2.10B
Revenue:
$418.33M
Net Income/Loss:
$-252.07M
P/E Ratio:
-7.8208
EPS:
-2.4
Net Cash Flow:
$-238.84M
1W Performance:
+10.54%
1M Performance:
+2.07%
6M Performance:
-45.29%
1Y Performance:
-32.89%
1-Day Range:
$18.40
$19.12
1-Week Range:
$16.96
$20.00
52-Week Range:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
18.77 | 2.13B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit - Yahoo Finance
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Zai Lab (NASDAQ:ZLAB) Stock Price - MarketBeat
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
Zai Lab (NASDAQ:ZLAB) Reaches New 1-Year Low – Time to Sell? - Defense World
Is UBS’s Global-Innovation Framing Rewriting Zai Lab’s (ZLAB) Long-Term Biopharma Platform Narrative? - Sahm
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform - Finviz
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month LowHere's Why - MarketBeat
8 High Growth Chinese Stocks To Buy - Insider Monkey
Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Short Interest in AiRWA Inc. (NASDAQ:YYAI) Rises By 24.6% - Defense World
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8% - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - Defense World
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Animalcare Group (LON:ANCR) Stock Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
Simply Good Foods (NASDAQ:SMPL) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
How Investors May Respond To Zai Lab (ZLAB) Winning Expanded China Approval For AUGTYRO Cancer Therapy - Sahm
Zai Lab (NASDAQ:ZLAB) Shares Gap UpWhat's Next? - MarketBeat
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
UBS gives Zai Lab (ZLAB) a buy rating - MSN
Zai Lab (NASDAQ:ZLAB) Research Coverage Started at UBS Group - Defense World
UBS Gives Zai Lab (ZLAB) a Buy Rating - Insider Monkey
Zai Lab (ZLAB) Is Up 7.9% After First-In-China AUGTYRO Approval Across TRK TKI Settings - Sahm
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - BioSpace
China clears new AUGTYRO use for adults with NTRK‑positive cancers - Stock Titan
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Nah? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares - Defense World
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Fade? - AD HOC NEWS
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts - TechStock²
EBITDA per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025 - ts2.tech
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Sahm
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CapEx per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial - Sahm
Zai Lab (NASDAQ:ZLAB) Hits New 12-Month LowTime to Sell? - MarketBeat
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals - Sahm
Zai Lab (NASDAQ:ZLAB) Hits New 1-Year LowShould You Sell? - MarketBeat
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire
Zai Lab Announces Updates to China’s National Reimbursement Drug List - Business Wire
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):